Schulte Imke, Tammen Harald, Selle Hartmut, Schulz-Knappe Peter
BioVisioN AG, Feodor-Lynen-Str. 5, 30625 Hannover, Germany.
Expert Rev Mol Diagn. 2005 Mar;5(2):145-57. doi: 10.1586/14737159.5.2.145.
The general awareness of the importance of peptides in physiology and pathophysiology has increased strongly over the last few years. With worldwide progress in the analysis of whole genomes, the knowledge base in gene sequence and expression data useful for protein and peptide analysis has drastically increased. The medical need for relevant biomarkers is enormous. This is particularly true for the many types of cancer, but other diseases such as Type 2 diabetes also lack useful and adequate diagnostic markers with high specificity and sensitivity. Despite advances in imaging technologies for early detection of diseases, proteomic and peptidomic multiplex techniques have evolved in recent years. This review focuses on the application of peptidomics technologies to peptides in health and disease. Peptidomics technologies provide new opportunities for the detection of low-molecular-weight proteome biomarkers (peptides) by mass spectrometry. Improvements in peptidomics research are based on separation of peptides and/or proteins by their physicochemical properties in combination with mass spectrometric detection, identification and sophisticated bioinformatics tools for data analysis. Therefore, peptidomics technologies offer an opportunity to discover novel biomarkers for diagnosis and management of disease (e.g., prognosis, treatment decision and monitoring response to therapy).
在过去几年中，人们对肽在生理学和病理生理学中的重要性的总体认识大幅提高。随着全球全基因组分析的进展，可用于蛋白质和肽分析的基因序列和表达数据的知识库急剧增加。对相关生物标志物的医学需求巨大。这在多种癌症类型中尤为如此，但其他疾病，如2型糖尿病，也缺乏具有高特异性和敏感性的有用且充分的诊断标志物。尽管疾病早期检测的成像技术有所进步，但蛋白质组学和肽组学多重技术近年来仍在不断发展。本综述聚焦于肽组学技术在健康和疾病中的肽的应用。肽组学技术为通过质谱检测低分子量蛋白质组生物标志物（肽）提供了新机会。肽组学研究的改进基于根据肽和/或蛋白质的物理化学性质进行分离，并结合质谱检测、鉴定以及用于数据分析的复杂生物信息学工具。因此，肽组学技术为发现用于疾病诊断和管理（如预后、治疗决策和监测治疗反应）的新型生物标志物提供了机会。
